June 12 (Tue.)

Memorial Lecture 1
9:00-9:30 Room 1

Shiro Naoe / Tsutomu Saji Memorial Lecture

Moderator: Masato Takahashi (Department of Cardiology University of Southern California Keck School of Medicine, California, USA)

ML1-1 In Memoriam: Professor Shiro Naoe (1937-2017)
Kei Takahashi (Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan)

ML1-2 A Distinguished Japanese Pediatrician Devoted Himself to Patient Care, Scientific Research, and Education
Hiroyuki Matsuura (Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan)

Oral Presentation 1
9:30-11:20 Room 1

Acute Phase ① Diagnosis, Treatment, Biomarker

Moderators: Hiroyuki Suzuki (Pediatrics, Wakayama Medical University, Wakayama, Japan)
David R. Fulton (Department of Cardiology, Boston Children's Hospital, Massachusetts, USA)

OP1-1 Approach to Finding a Biomarker to Diagnose Serious Kawasaki Disease
Yasuhiro Katsube (Pediatrics, Nippon Medical School Musashi-kosugi Hospital, Tokyo, Japan)

OP1-2 Biomarkers in Kawasaki Disease: An Overview
David Burgner (Senior Research Fellow and Paediatric Infectious Diseases Physician, Murdoch Children’s Research Institute, Royal Children’s Hospital, Victoria, Australia)

OP1-3 Biomarkers in Kawasaki Disease: Management and Prognosis
Sarah de Ferranti (Department of Cardiology, Boston Children’s Hospital, Massachusetts, USA)

OP1-4 Identification of Candidate Diagnostic Serum Biomarkers for Kawasaki Disease Using Proteomic Analysis
Masaaki Mori (Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan)
OP1-5  Lipid Profiles in Children with Kawasaki Disease Compared to Children with Acute Bacterial Infections  
Pei-Ni Jone (Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, Colorado, USA)

OP1-6  A Comparison of Efficacy of Six Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease  
Tang Yunjia (Department of Cardiology, Children’s Hospital of Soochow University, Jiangsu, China)

OP1-7  The Efficacy of Immunoglobulin Plus Decreased Duration of Prednisolone for Kawasaki Disease Patients with High Risk for Coronary Abnormalities  
Taichi Kato (Department of Pediatrics/Developmental Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan)

Memorial Lecture 2

11:30-12:00  Room 1

Hideko Ogawa Memorial Lecture

Moderator: Hirohisa Kato (Professor emeritus of Pediatrics, Kurume University, Fukuoka, Japan)

ML2  Forty Years’ Experience of Nationwide Epidemiological Survey of Kawasaki Disease in Japan  
Hiroshi Yanagawa (Department of Public Health, Jichi Medical University, Tochigi, Japan)

Luncheon Seminar 1

12:10-13:00  Room 1

FROM BEDSIDE TO GENERATING HIGH-QUALITY EVIDENCE: JAPANESE MULTICENTER EXPERIENCES

Moderator: Masaru Miura (Vice-President, Tokyo Metropolitan Children's Medical Center)

LS1  Tohru Kobayashi (Director in Department of Management and Strategy, Chief in Division of Biostatistics and Division of Data Management, Clinical Research Center, National Center for Child Health and Development)

Sponsored by Japan Blood Products Organization
Round Table Discussion

14:00-15:30 Room 1

AHA Guideline vs Japan Guideline

Moderators: Brian W. McCrindle (Department of Pediatrics, University of Toronto, Ontario, Canada)
Mamoru Ayusawa (Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan)

RTD-1 2017 American Heart Association Scientific Statement on Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
Jane W. Newburger (Department of Cardiology, Boston Children’s Hospital, Massachusetts, USA)

RTD-2 How to Diagnose Kawasaki Disease – Current Situation in Japan –
Mamoru Ayusawa (Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan)

RTD-3 The 2017 AHA Update Nomenclature and Definition of the Coronary Artery Aneurysm. Arguments Against a Misleading Case Definition
Nagib Dahdah (Division of Pediatric Cardiology, Department of Pediatrics, University of Montreal, Quebec, Canada)

RTD-4 AHA Guideline Versus Japan Guideline: Taiwan Perspectives
Mei-Hwan Wu (Cardiology, National Taiwan University Children’s Hospital, Taipei, Taiwan)

RTD-5 Clinical Experience and Diagnosis of Kawasaki Disease in Patients Presenting with Limited and Faint Principal Clinical Features
Yuichi Nomura (Department of Pediatrics, Kagoshima City Hospital, Kagoshima, Japan)

Symposium 1

15:40-16:40 Room 1

Japan / China / Mongolia Joint Symposium: Epidemiology

Moderators: Yoshikazu Nakamura (Department of Public Health, Jichi Medical University, Tochigi, Japan)
Ermias Belay (Centers for Disease Control and Prevention, Georgia, USA)

SY1-1 Epidemiology of Kawasaki Disease in Japan; Hypothesis about the Etiology
Nobuko Makino (Public Health, Jichi Medical University, Tochigi, Japan)

SY1-2 Epidemiologic Features of Kawasaki Disease in China
Zhong-Dong Du (Beijing Children’s Hospital, Capital Medical University, Beijing, China)

SY1-3 Current Situation of Kawasaki Disease in Mongolia: Preliminary Results of the Third Nationwide Survey
Dambadarjaa Davaalkham (Department of Epidemiology and Biostatistics, School of Public Health, Mongolia National University of Medical Sciences, Ulaanbaatar, Mongolia)
Moderated Poster Session 1

16:40-17:40 Room 1

Epidemiology

Moderators: Ryusuke Ae (Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan) Eeva Salo (Children’s Hospital, University of Helsinki, Helsinki, Finland)

MPS1-1 The Interaction between Patients’ Age and Sex and the Development of Coronary Artery Lesions Attributable to Kawasaki Disease in Japan
Naomi Kitano (Research Center for Community Medicine, Wakayama Medical University, Wakayama, Japan)

MPS1-2 Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014
Gi Beom Kim (Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea)

MPS1-3 Kawasaki Disease- An Eastern Indian Cohort Over 8 Years
Priyankar Pal (Department of Pediatric Rheumatology, Institute of Child Health, West Bengal, India)

MPS1-4 Clinical Analysis of Hospitalized Children with Kawasaki Disease Based on E-Science Model, Single Center Registry from 2009 to 2016
Tingting Xiao (Shanghai Children's Hospital Affiliated to Shanghai Jiaotong University Cardiology Department, Shanghai, China)

MPS1-5 Kawasaki Disease Epidemiology in Latin American Children and the Impact of the REKAMLATINA Network (Latin American Kawasaki Disease Network)
Rolando Ulloa-Gutierrez (Servicio de Infectologia Pediatrica, Hospital Nacional de Niños "Dr. Carlos Saens Herrera", San Jose, Costa Rica)

MPS1-6 Kawasaki Disease Occurrence in the United States
Ryan A. Maddox (Centers for Disease Control and Prevention, Georgia, USA)

MPS1-7 Epidemiology of Kawasaki Disease in Hawaii
Yuri Endo (Hawaii’s Residency Program, University of Hawaii'i, Hawaii'i, USA)

MPS1-8 Kawasaki Disease Incidence among Children of Different Races and Ethnicities in Hawaii, 2005-2014
Ermias D. Belay (Centers for Disease Control and Prevention, Georgia, USA)

MPS1-9 Severity of Coronary Artery Aneurysms in Infants with Kawasaki Disease
Anne H. Rowley (Pediatrics, Northwestern University Feinberg School of Medicine, Illinois, USA)
MPS1-10 Regional-Scale Climate Patterns and Spatiotemporal Structure of Kawasaki Disease in San Diego Suggest Environmental Trigger

Martin Rypdal (Department of Mathematics and Statistics, UiT the Arctic University of Norway, Tromso, Norway)

MPS1-11 Cumulative Incidence of Kawasaki Disease with Late-Stage Cardiac Sequelae in Japan

Yuri Matsubara (Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan)
**June13 (Wed.)**

### Morning Seminar 1

7:30-8:20 Room 1

**Current progress in the treatment of acute illness for Kawasaki Disease**

Moderator: Ryuji Fukazawa (Department of Pediatrics, Nippon Medical School, Tokyo, Japan)

**MS1**

Hiromichi Hamada (Department of Pediatrics, Yachiyo Medical Center, Tokyo Women's Medical University, Chiba, Japan)

Sponsored by NIHON PHARMACEUTICAL Co., Ltd.

### Oral Presentation 2

8:30-9:50 Room 1

**Basic study ① Pathology/Pathogenesis/Etiology**

Moderators: Toshiaki Oharaseki (Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan)
Anne H. Rowley (Pediatrics, Northwestern University Feinberg School of Medicine, Illinois, USA)

**OP2-1** The Pathogenesis/Pathophysiology of Kawasaki Disease: A Keynote Address
Toshiro Hara (Fukuoka Children's Hospital, Fukuoka, Japan)

**OP2-2** Role of Hypoxia Pathway in Vascular Inflammation and Coronary Dilation: A New Mouse Model of Kawasaki Disease
Silvia Martin-Puig (Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain)

**OP2-3** Dectin-2 Is Necessary for Developing Vasculitis in Animal Model of Kawasaki Disease
Toshiaki Oharaseki (Department of Pathology, Toho University Ohahi Medical Center, Tokyo, Japan)

**OP2-4** Expansion of Clonally Related Plasmablasts in Peripheral Blood of Kawasaki Disease Patients
Anne H. Rowley (Pediatrics, Northwestern University Feinberg School of Medicine, Illinois, USA)

**OP2-5** eQTL Highlights the Potential Role of Negatively Control of Innate Immunity in Kawasaki Disease
Sirui Song (Cardiology Department, Shanghai Children's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China)

Sponsored by Japan Kawasaki Disease Research Center
Oral Presentation 3

10:10-11:30 Room 1

Basic study (2) Genetics

Moderators: Jun Abe (Division of Advanced Medicine for Virus Infections, National Center for Child Health and Development, Tokyo, Japan)
Taco W. Kujipers (Emma Children’s Hospital Academic Medical Center Noord-Holland, the Netherlands)

OP3-1 Recent Advances in Genetic Studies of Kawasaki Disease in Japan
Yoshihiro Onouchi (Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan)

OP3-2 Transcriptomic Analysis of Fc Receptors in Kawasaki Disease
Ling-Sai Chang (Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan)

OP3-3 FCGR2C-ORF Haplotype is Strongly Associated with Kawasaki Disease in Caucasians but Absent in Asian Populations
Taco W. Kuijpers (Emma Children's Hospital AMC, Academic Medical Center, Amsterdam, the Netherlands)

OP3-4 Bifid T Waves on the Electrocardiogram are Associated with Genetic Variation in Calcium Channel Voltage-Dependent beta 2 Subunit Gene (CACNB2) in Acute Kawasaki Disease
Jun Oyamada (Department of Pediatrics, Ogachi Central Hospital, Akita, Japan)

OP3-5 Integrative Analysis of Multi-Omics Data for Coronary Artery Aneurysm Formation among Kawasaki Disease Patients
Jihoon Kim (Biomedical Informatics, University of California San Diego, California, USA)

Memorial Lecture 1

11:30-12:00 Room 1

Yuki Lynn Memorial Lecture

Moderator: Masato Takahashi (Department of Cardiology University of Southern California Keck School of Medicine, California, USA)

ML3 The Role of Experimental Mouse Models in Accelerating Research Progress in Pathogenesis of Kawasaki Disease. Recent Paradigm Shifts
Moshe Arditi (Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center; David Geffen School of Medicine at University of California Los Angeles (UCLA), California, USA)
Luncheon Seminar 2
12:10-13:00 Room 1

**Adult Kawasaki Disease**

Moderator: Masahiro Ishii (Kitasato University School of Medicine, Kanagawa, Japan)

**LS2-1** Kenji Suda (Department of Pediatrics, Kurume University, Kurume, Japan)

**LS2-2** John B. Gordon (San Diego Cardiac Center, California, USA)

Sponsored by Pediatric Alumni Association in Kurume University

Afternoon Seminar
14:00-14:50 Room 1

**CVIT-JSKD Joint Lecture**

Moderator: Kei Takahashi (Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan)

**AS1** Current Status and Future Perspectives of Bioresorbable Vessel Scaffold and Drug Eluting Stent
Masato Nakamura (Department of cardiovascular medicine, Toho University Ohashi Medical Center, Tokyo, Japan)

Sponsored by TERUMO Corporation

Moderated Poster Session 2
15:00-16:00 Room 1

**Acute Phase**

Moderators: Tsuneyuki Nakamura (Department of Pediatric Cardiology, Kanazawa Medical University Hospital, Ishikawa, Japan)
Ji-Whan Han (Department of Pediatrics, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea)

**MPS2-1** Clinical Significance of the Reaction at BCG Inoculation Site in Children with Kawasaki Disease under 18 Months
Sunghyeon Park (Department of Pediatrics, Asan Medical Center, Seoul, Korea)

**MPS2-2** Gastrointestinal Presentation of Kawasaki Disease: A Red Flag for Severe Disease?
Marianna Fabi (Department of Pediatrics, Sant'Orsola Malpighi University Hospital, Emilia-Romagna, Italy)

**MPS2-3** Diagnosis of Kawasaki Disease Using a Thirteen Gene Expression Signature
Jethro A Herberg (Section of Paediatrics, Imperial College, London, UK)
**MPS2-4** Multi-Center Validation of a Computer-Based Tool for Differentiation of Acute Kawasaki Disease from Clinically Similar Febrile Illnesses
Shiying Hao (Department of Surgery, Stanford University, Stanford, California, USA)

**MPS2-5** Optimal Coronary Interpretation and Correlation to Acute Kawasaki Disease Using End-Diastole Image: The Impact on Inter-Observer Variation
Tai I Hsin (Department of Pediatrics, Kaohsiung Chang Sung Memorial Hospital, Kaohsiung, Taiwan)

**MPS2-6** The Establishment of New Scoring Model for IVIG Non-Response of Kawasaki Disease
Min Huang (Shanghai Children's Hospital Affiliated to Shanghai Jiaotong University Cardiology Department, Shanghai, China)

**MPS2-7** Prediction of Unresponsiveness to Intravenous Immunoglobulin in Patients with Kawasaki Disease Less Than One Year Old
Natsuko Suzuki (Department of Pediatrics, Musashino Red Cross Hospital, Tokyo, Japan)

**MPS2-8** Predicting Intravenous Immunoglobulin (IVIG) Resistance and Targeting Second-Line Therapeutic Choice Through Machine Learning Algorithms by Using Early Fever Profile
Cedric Manlhiot (Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Ontario, Canada)

**MPS2-9** Studies on the Differences in Prognosis between Children Treated with Antibiotics and Nonusers Prior to the Diagnosis of Kawasaki Disease
Zon-Min Lee (Kawasaki Disease Center and Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan)

**MPS2-10** Prognosis of Patients with Kawasaki Disease Who Have Already Developed Coronary Artery Lesions before Initial Intravenous Immunoglobulin Treatment: Results from the 23rd Nationwide Survey of Kawasaki Disease in Japan
Hiromi Muta (Iizuka Children's Clinic, Fukuoka, Japan)

**MPS2-11** A Randomized Multicenter Double-Blind Placebo Controlled Trial of Etanercept for Acute Kawasaki Disease
Michael A Portman (Cardiology, Seattle Children's Hospital, Washington, USA)
Oral Presentation 4
16:00-17:30 Room 1

Acute Phase ② Treatment

Moderators: Tomoyo Matsubara (Department of Pediatrics, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan)
Mei-Hwan Wu (Cardiology, National Taiwan University Children’s Hospital, Taipei, Taiwan)

OP4-1 Second Line Treatment in Kawasaki Disease
Elif Seda Selamet Tierney (Pediatrics/Cardiology, Stanford University, California, USA)

OP4-2 Treatment of Kawasaki Disease during the Acute Phase
Surjit Singh (Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India)

OP4-3 Multicenter Study on Current Status of Treating Intravenous Immunoglobulin Resistant Kawasaki Disease with Infliximab in Korea
Min Seob Song (Department of Pediatrics, Inje University, Haeundae Paik Hospital, Busan, Korea)

OP4-4 Should the initial treatment of kawasaki disease (KD) be the same in all patients?
Isabelle Kone-Paut (Head Paediatric rheumatology department, Coordinator of the CEREMAIA, Bicetre hospital, APHP. University of Paris Sud, France)

OP4-5 Quenching the Inflammatory Fire of Acute KD
Adriana H. Tremoulet (Department of Pediatrics, University of California San Diego, California, USA)

Parents Association Activity
18:00-19:00

Moderator: Mamoru Ayusawa (Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan)
Morning Seminar 2

7:30-8:20 Room 1

Cardiovascular function after Kawasaki disease While considering support for provincial medicine for children

Moderator: Hideaki Senzaki (Kitasato University Support of Provincial Medicine for Pediatrics and Pediatric Cardiology (donated from Iwaki-shi))

MS2-1 Present status of pediatric medicine in Iwaki
Masato Abe (Iwaki-shi Regional Medical Care Division, Fukushima, Japan)

MS2-2 Overview and perspective of our project to support provincial medicine for children
Hideaki Senzaki (Department of Pediatrics, Kitasato University)

MS2-3 Cardiovascular function after Kawasaki disease
Satoshi Masutani (Associate professor of Saitama Medical University)

Supported by Kitasato University Support of Provincial Medicine for Pediatrics and Pediatric Cardiology (donated from Iwaki-shi)

Moderated Poster Session 3

8:30-9:10 Room 1

Animal model, Pathology, Etiology

Moderators: Kyoko Imanaka-Yoshida (Pathology and Matrix Biology, Mie University Graduate School of Medicine, Mie, Japan)
Stanford Shulman (Pediatric Infections Diseases, Lusie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Illinois, USA)

MPS3-1 Role of Intestinal Permeability and Secretory IgA in a Murine Model of Kawasaki Disease Vasculitis
Magali Noval Rivas (Division of Pediatric Infectious Diseases and Immunology, Departments of Pediatrics and Biomedical Science, Cedars-Sinai Medical Center, California, USA)

MPS3-2 Oxidative Stress in Kawasaki Disease Vasculitis: Is the Oxidative Stress the Possible Therapeutic Target for Vascular Inflammation?
Akiko Hamaoka-Okamoto (Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan)
MPS3-3 Berberine Protects Human Coronary Artery Endothelial Cells from Injury Induced by Kawasaki Disease through Regulating of Endoplasmic Reticulum Stress
Mingguo Xu (Department of Pediatric Cardiology, Shenzhen Children's Hospital, Guangdong, China)

MPS3-4 MicroRNA-145-5p and MicroRNA-320a Encapsulated in Endothelial Microparticles Contribute to the Progression of Vasculitis in Acute Kawasaki Disease
Hideyuki Nakaoka (Department of Pediatrics, National Cerebral and Cardiovascular Center, Osaka, Japan)

MPS3-5 Kawasaki Disease-Specific Molecules are Associated with the Degree of Inflammation, IVIG-Resistance and the Formation of Coronary Artery Lesions in Kawasaki Disease
Yasutaka Nakashima (Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan)

MPS3-6 Host Protein Sequencing Profile Reveals Unique Signatures in Kawasaki Disease
Stephanie Menikou (Section of Pediatrics, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK)

Moderated Poster Session 4
9:10-9:50 Room 1

Genetics, Immunology
Moderators: Kazuyuki Ikeda (Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan)
Shohei Ogata (Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan)

MPS4-1 Investigation of Novel Variations of ORAI1 Gene and Their Association with Kawasaki Disease
Kyaw Thiha (Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan)

MPS4-2 BCL2L11 is Associated with Kawasaki Disease in Intravenous Immunoglobulin Responder Patients
Young-Chang Kwon (Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea)

MPS4-3 Relationship of Three Gene Polymorphisms Related to Ca2+/NFAT-Pathway with Clinical Characteristics in the Acute Phase of Kawasaki Disease
Takayuki Suzuki (Department of Pediatrics, Wakayama Medical University, Wakayama, Japan)
MPS4-4  Acute Kawasaki Disease is Associated with Elevated mRNA Expression of M2 Macrophage Markers and Hypomethylation of Corresponding CpG Sites
Mindy M. Guo (Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan)

MPS4-5  A Comprehensive Analysis of Massive Peripheral Blood Mononuclear Cell Samples in Kawasaki Disease
Ebato Takasuke (Department of Pediatrics, Kitasato University, School of Medicine, Kanagawa, Japan)

MPS4-6  Differences in Innate Immune Responses to in-vitro Stimulation with Toll-Like Receptor and NLRP3 Inflammasome Ligands following Kawasaki Disease and Toxic Shock Syndrome
Katherine Ya-Hui Chen (Murdoch Childrens Research Institute, Parkville, Victoria, Australia)

MPS4-7  Withdrawn

Moderated Poster Session 5
10:20-11:30  Room 1

Long Term

Moderators: Ryuji Fukazawa (Pediatrics, Nippon Medical School, Tokyo, Japan)
Lucy Yougmin Eun (Division of Pediatric Cardiology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea)

MPS5-1  What Role Do the Vasa Vasorum Play in the Sequelae of Coronary Arterial Lesions in Kawasaki Disease?
Nobuyuki Kakimoto (Department of Pediatrics, Wakayama Medical University, Wakayama, Japan)

MPS5-2  Specific Differences in Distal and Proximal Artery Mechanics following Kawasaki Disease with Normal Coronary Arteries
Roch L. Maurice (Service de Cardiologie, Centre Hospitalier Universitaire Sainte-Justine (CHUSJ), University of Montreal, Quebec, Canada)

MPS5-3  Altered Lipid Profile after Kawasaki Disease in Mexican Children
Netzi Sanchez (Endocrinology Department, Instituto Nacional de Pediatria, Mexico City, Mexico)

MPS5-4  Stress Cardiac MRI in Patients with Kawasaki Disease and Coronary Artery Aneurysms: A Comparison to Conventional Angiography
Dionysios Pepelassis (Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada)

MPS5-5  Long-Term Analysis of Coronary Artery Distensibility Assessed Automatically via Angiography in Kawasaki Disease
Mitchel Benovoy (Corstem Inc., Montreal, Quebec, Canada)
**Program**

**MPS5-6** Complementary Coronary Artery Assessment in Kawasaki Disease with Low-Dose CT Angiography to Uncover Vascular Pathology
Diana van Stijn - Bringas Dimitriades (Department of pediatric hematology, immunology and infectious diseases, Emma Children's Hospital, Academic Medical Centre (AMC), Noord-Holanda, the Netherlands)

**MPS5-7** Characterization of Coronary Artery Tissues in Kawasaki Disease Using Optical Coherence Tomography (OCT) Imaging
Atefeh Abdolmanafi (Department of Software and IT Engineering, Ecole de technologie superieure, Quebec, Canada)

**MPS5-8** Withdrawn

**MPS5-9** Evaluation of the Vascular Remodeling in Patients Long after Kawasaki Disease by Contrast-Enhanced Carotid Ultrasonography
Akiko Komori (Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan)

**MPS5-10** The Prognosis of Large Coronary Artery Aneurysm in Children with Kawasaki Disease
Xu Xinyi (Department of Cardiology, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China)

**MPS5-11** Long-Term Health in Young Adults with a History of Kawasaki Disease and Normal Coronary Arteries
Lori B Daniels (University of California, California, USA)

**MPS5-12** Long-Term Antithrombosis Management of Patients with Kawasaki Disease; Results from an International Survey
Audrey Dionne (Department of Cardiology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Massachusetts, USA)

### Memorial Lecture 4

**11:30-12:00 Room 1**

**Richard D Rowe Memorial Lecture**
Moderator: Brian W. McCrindle (Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Ontario, Canada)

**ML4** Toward Lifelong Cardiology in Kawasaki Disease
Yoshihide Mitai (Department of Pediatrics and Pediatric Cardiology, Mie University Graduate School of Medicine, Mie, Japan)
**Luncheon Seminar 3**

**12:10-13:00**

**Room 1**

**Differential diagnosis and pitfalls in Kawasaki disease: Is it really Kawasaki disease?**

**Moderator:** Hiroyuki Suzuki (Professor and Chairman, Department of Pediatrics, Wakayama Medical University, Wakanama, Japan)

**LS3** Shuichi Ito (Department of Pediatrics, Yokohama City University, Graduate School of Medicine, Kanagawa, Japan)

*Sponsored by Teijin Pharma Limited*

---

**Presidents Lecture**

**14:00-14:40**

**Room 1**

**Moderator:** Hirohisa Kato (Professor emeritus of Pediatrics, Kurume University, Fukuoka, Japan)

**PL-1** Update on Kawasaki Disease from Pathophysiology to Medical Therapy

Masahiro Ishii (Kitasato University, Kanagawa, Japan)

**PL-2** Systemic Vasculitis in Kawasaki Disease

Kei Takahashi (Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan)

---

**Symposium 2**

**14:40-16:10**

**Room 1**

**Alternative Treatment**

**Moderators:** Keiji Tsuchiya (Pediatrics, Japanese Red Cross Medical Center, Tokyo, Japan)
Adriana H. Tremoulet (Pediatrics, University of California San Diego, California, USA)

**SS-1** Current Status of Biologic Product Clinical Trials for Acute Kawasaki Disease in the U.S.

Jane C. Burns (Department of Pediatrics, University of California San Diego, California, USA)

**SS-2** Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan

Tohru Kobayashi (Department of Management and Strategy, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan)

**SS-3** Therapies Targeting TNF-Alpha Against IVIG Resistant Kawasaki Disease; Infliximab and Plasma Exchange

Shuichi Ito (Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan)
Program

SS-4 Progress of a Randomized Trial of Immunoglobulin Plus Cyclosporin A in Patients with Kawasaki Disease Who Are Predicted to Be Non-Responders to Initial Treatment (KAICA Trial)
Hiromichi Hamada (Chiba University Graduate School of Medicine and Department of Pediatrics, and Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, Japan)

SS-5 Prospective Observational Study on Efficacy and Safety of Stratified Treatment with Immunoglobulin Plus Steroid for Kawasaki Disease (Post RAISE)
Koichi Miyata (Department of Cardiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan)

Sponsored by Mitsubishi Tanabe Pharma Corporation

Oral Presentation 5
16:10-17:30 Room 1

Long Term

OP5-1 Long-Term Prognosis and Management of Coronary Artery Complications
Brian W. McCrindle (Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Ontario, Canada)

OP5-2 Establishment of a Registry Study of Kawasaki Disease Patients with Coronary Artery Aneurysms (KIDKAR)
Masaru Miura (Department of Cardiology, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan)

OP5-3 Long Term Vascular Health in Kawasaki Disease
Yiu-Fai Cheung (Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China)

OP5-4 Hemodynamic Simulations to Stratify Thrombotic Risk in Kawasaki Disease Patients with Coronary Artery Aneurysms
Noelia Grande Gutierrez (Department of Mechanical Engineering, Stanford University, California, USA)

OP5-5 Long-Term Changes and Characteristics of Coronary Aneurysms Caused by Kawasaki Disease
Etsuko Tsuda (Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan)
Program

June 15 (Fri.)

**Oral Presentation 6**

8:30-10:00 Room 1

**Socio-economic Issue, Psychosocial Issue, Transition**

Moderators: Satoshi Yasukouchi (Heart Center, Nagano Children’s Hospital, Nagano, Japan)
Ming-Tai Lin (Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan)

**OP6-1** Environmental Problems of Adulthood Kawasaki Disease Patients -From Patients Perspectives-
Atsushi Kawakubo (Parents Association Kawasaki Disease, Japan)

**OP6-2** Surveillance of the Current Follow-Up Status of the Adult Kawasaki Disease Patients with Giant Aneurysm
Hiroshi Katayama (Department of Pediatrics, Osaka Medical College, Osaka, Japan)

**OP6-3** Principles of Transition to Adult Care for Patients with Kawasaki Disease and Coronary Artery Aneurysms
Annette Baker (Department of Cardiology, Boston Children’s Hospital, Massachusetts, USA)

**OP6-4** Current Status of Health Care Transition in Adults with Coronary Arterial Lesions in Japan
Hiroshi Kamiyama (Center for Institutional Research and Medical Education, Nihon University School of Medicine, Tokyo, Japan)

**OP6-5** Psychosocial Adaptation: A Prediction Model for Parents and Children with Complex Kawasaki Disease
Nita Chahal (The Labatt Family Heart Center, The Hospital for Sick Children, Ontario, Canada)

**OP6-6** Our Experience of Setting a Kawasaki Disease Service for Adult and Children at the Royal Brompton Hospital
Elena Karagodova (Royal Brompton & Harefield NHS Foundation Trust Royal Brompton Hospital, London, UK)

**Summary & Discussion**

10:00-11:00 Room 1

Moderators: Jane C. Burns (Department of Pediatrics, USCD, USA)
Jane W. Newburger (Department of Cardiology, Boston Children’s Hospital, UK)
Jane C. Burns (Department of Pediatrics, USCD, USA)
Jane W. Newburger (Department of Cardiology, Boston Children’s Hospital, UK)